Messenger RNA vaccines against SARS-CoV-2
EJ Topol - Cell, 2021 - Elsevier
Cell, 2021•Elsevier
The first two vaccines proven to be effective for inhibiting COVID-19 illness were both
mRNA, achieving 95% efficacy (and safety) among 74,000 participants (half receiving
placebo) after intramuscular delivery of two shots, 3–4 weeks apart. To view this Bench to
Bedside, open or download the PDF.
mRNA, achieving 95% efficacy (and safety) among 74,000 participants (half receiving
placebo) after intramuscular delivery of two shots, 3–4 weeks apart. To view this Bench to
Bedside, open or download the PDF.
Summary
The first two vaccines proven to be effective for inhibiting COVID-19 illness were both mRNA, achieving 95% efficacy (and safety) among 74,000 participants (half receiving placebo) after intramuscular delivery of two shots, 3–4 weeks apart. To view this Bench to Bedside, open or download the PDF.
Elsevier